ML-SA1 

ML-SA1, as a selective TRPML agonist, inhibits Dengue virus 2 (DENV2) and Zika virus (ZIKV) by promoting lysosomal acidification and protease activity. The IC₅₀ value of ML-SA1 against DENV2 RNA and ZIKV RNA is 8.3 μM and 52.99 μM, respectively. ML-SA1 induces autophagy. ML-SA1 can be used for the research of broad-spectrum antiviral^[1].

IC50: 8.3 μM (DENV2)^[1].
IC50: 52.99 μM (ZIKV)^[1]

ML-SA1 (25 μM; 0~14 hours; A549 cells) possibly affects the entry of DENV2 into host cells^[1].
ML-SA1 (0~200 μM; A549 cells) shows that there is no cytotoxicity to the cell line observed, even at concentrations up to 200 μM. ML-SA1 (0~50 μM; A549 cells) significantly suppresses DENV2 at the RNA levels and the IC₅₀ is 8.93 μM^[1]. ML-SA1 results in a dose-dependent decrease in ZIKV in A549 cells at both the RNA and protein levels, and the IC₅₀ value of ML-SA1 against ZIKV RNA is 52.99 μM. ML-SA1, as an activator of TRPMLs, appears to be a potent inhibitor of DENV2 and ZIKV in vitro. ML-SA1 promotes lysosomal acidification and protease activity to inhibit viral infection. ML-SA1 can induce autophagy in Huh7 cells or A549 cells^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

362.42

Solid

C₂₂H₂₂N₂O₃

332382-54-4

O=C1N(CC(N2C(C)(C)CC(C)C3=C2C=CC=C3)=O)C(C4=C1C=CC=C4)=O

Room temperature in continental US; may vary elsewhere.

• [1]. Xia Z, et al. ML-SA1, a selective TRPML agonist, inhibits DENV2 and ZIKV by promoting lysosomal acidification and protease activity. Antiviral Res. 2020;182:104922.  [Content Brief]